uptake mechanism, has demonstrated broad spectrum efficacy against Gram-negative pathogens. They are developing GT-1 for serious bacterial infections, including those caused by MDR P. aeruginosa and Acinetobacter spp. They have built an exceptional research and development team with deep expertise in the development of new antibiotics from discovery through approval. Their mission is to improve patients’ lives by developing novel antibiotics to treat resistant infections for which there are no available therapies.